Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study

Objectives : Fluconazole is widely used for the treatment of candidiasis. Although the drug is also prescribed to pregnant women, data on the safety of use of fluconazole during pregnancy are limited. We examined the association between the maternal use of fluconazole during pregnancy and the risk of congenital malformations. Patients and methods : In this population-based cohort study in Northern Denmark, we included 1079 women who had a live birth or a stillbirth after the 20th week of gestation and who redeemed at least one prescription for fluconazole during the first trimester. The reference cohort comprised 170 453 pregnant women who redeemed no fluconazole prescription during pregnancy. The women were identified through the Danish Medical Birth Registry. Data on drug use, birth outcome and covariates were extracted from population-based healthcare databases. We used logistic regression to estimate the prevalence odds ratio (POR) for congenital malformations after fluconazole exposure, while adjusting for maternal smoking, parity, maternal age and concurrent prescriptions for antiepileptics or antidiabetics. Results : Among 1079 women who filled a fluconazole prescription during the first trimester, 797 (74%) received a total of 150 mg of fluconazole, 235 (22%) received 300 mg of fluconazole, 24 (2%) received 350 mg of fluconazole and 23 (2%) received 600 mg of fluconazole. These women gave birth to 44 (4.1%) children with congenital malformations. The 170 453 women without fluconazole prescriptions gave birth to 6152 (3.6%) children with congenital malformations. For congenital malformations overall, the adjusted POR associated with the first-trimester fluconazole use was 1.0 (95% confidence interval: 0.8–1.4). Conclusions : We found no overall increased risk of congenital malformations after exposure to short-course treatment with fluconazole in early pregnancy.

[1]  Jing Shen,et al.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[2]  D. Hassiakos,et al.  Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[3]  M. V. Van Allen,et al.  Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. , 2005, Birth defects research. Part A, Clinical and molecular teratology.

[4]  V. Massa,et al.  Study on the common teratogenic pathway elicited by the fungicides triazole-derivatives. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[5]  K. Rothman,et al.  Risk of specific congenital abnormalities in offspring of women with diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[6]  J. Sobel,et al.  Fluconazole for the treatment of candidiasis: 15 years experience , 2004, Expert review of anti-infective therapy.

[7]  W. Inman,et al.  Safety of fluconazole in the treatment of vaginal candidiasis , 2004, European Journal of Clinical Pharmacology.

[8]  J. Sobel,et al.  Antifungal drugs in pregnancy: a review , 2003, Expert opinion on drug safety.

[9]  H. Sørensen,et al.  Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries , 2003, Scandinavian journal of public health.

[10]  A. Mitchell Special Considerations in Studies of Drug‐induced Birth Defects , 2002 .

[11]  K. Jones,et al.  Selection bias in Teratology Information Service pregnancy outcome studies. , 2001, Teratology.

[12]  E. Menegola,et al.  Antifungal triazoles induce malformations in vitro. , 2001, Reproductive toxicology.

[13]  L. Pedersen,et al.  Birth outcomes in women exposed to anticonvulsant drugs , 2000, Acta neurologica Scandinavica.

[14]  H. Sørensen,et al.  Risk of malformations and other outcomes in children exposed to fluconazole in utero. , 1999, British journal of clinical pharmacology.

[15]  S. Jick Pregnancy Outcomes after Maternal Exposure to Fluconazole , 1999, Pharmacotherapy.

[16]  J. Olsen,et al.  The Danish Medical Birth Registry. , 1998, Danish medical bulletin.

[17]  D. Bartley,et al.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. , 1997, American journal of medical genetics.

[18]  M. Bonati,et al.  Fluconazole Treatment for Vulvovaginal Candidiasis during Pregnancy , 1997, The Annals of pharmacotherapy.

[19]  P. Mastroiacovo,et al.  Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. , 1996, American journal of obstetrics and gynecology.

[20]  J. Abraham,et al.  Fluconazole-induced congenital anomalies in three infants. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Fleiss,et al.  The statistical basis of meta-analysis. , 1993, Statistical methods in medical research.

[22]  A. R. Murthy,et al.  Congenital malformations in an infant born to a woman treated with fluconazole. , 1992, The Pediatric infectious disease journal.

[23]  Gillian M. Morriss-Kay,et al.  Langman's Medical Embryology , 1991 .

[24]  P. Vanparys,et al.  Safety aspects of oral antifungal agents. , 1990, British journal of clinical practice. Supplement.

[25]  E. Niebuhr,et al.  Down's syndrome , 1974, Humangenetik.